3 citations,
October 2021 in “Journal of Cosmetic Dermatology” Trichoscopy helps tell apart Frontal Fibrosing Alopecia and Lichen planopilaris by showing different hair and scalp features.
1 citations,
March 2023 in “Clinical, Cosmetic and Investigational Dermatology” Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
1 citations,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The summit concluded that new treatments like Jak inhibitors show promise for Alopecia Areata and personalized approaches are needed.
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
April 2024 in “Cosmetics” Wigs help improve self-esteem and quality of life for people with hair loss from alopecia areata.
February 2024 in “International Journal of Molecular Sciences” Hair loss in Androgenetic Alopecia is caused by genetics, aging, and lifestyle, leading to hair follicle shrinkage and related health risks.
Nanocarriers with plant extracts show promise for safe and effective hair growth treatment.
October 2023 in “Skin health and disease” Alopecia areata costs individuals about 3% of their income, with women, Asians, those with lower income, and more severe symptoms spending more.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
May 2023 in “Journal of managed care & specialty pharmacy” Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
September 2016 in “Springer eBooks” Gray hair is caused by oxidative stress damaging hair cells.
March 2023 in “Anais Brasileiros De Dermatologia” Topical minoxidil is the best-supported treatment for female hair loss, but personalized plans are needed.
7 citations,
October 2015 in “Actas Dermo-Sifiliográficas” New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.
105 citations,
February 2017 in “British Journal of Dermatology” Survivors of Stevens-Johnson syndrome/toxic epidermal necrolysis need ongoing care for various long-term health problems.
17 citations,
November 2018 in “Dermatology” Most patients with frontal fibrosing alopecia had facial bumps, with Hispanic/Latino and premenopausal women being more affected, suggesting a more severe condition.
47 citations,
January 2013 in “International Journal of Cosmetic Science” Hair diversity is influenced by complex genetics and environmental factors, requiring more research for practical solutions.
18 citations,
January 2017 in “Postępy Dermatologii i Alergologii” EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
2 citations,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
69 citations,
April 2010 in “Dermatologic Surgery” Bimatoprost is a safe and effective treatment for making eyelashes longer, thicker, and darker.
55 citations,
March 2009 in “Journal of The American Academy of Dermatology” Topical latanoprost and bimatoprost eye solutions don't help eyelash growth in people with alopecia areata.
50 citations,
December 2009 in “Journal of The European Academy of Dermatology and Venereology” Latanoprost can effectively treat eyelash hair loss, with 45% of patients showing hair regrowth and no reported side effects.
39 citations,
May 2013 in “Optometry and vision science” A new way to find eyelash mites without pulling out eyelashes.
38 citations,
October 2014 in “British journal of dermatology/British journal of dermatology, Supplement” Bimatoprost solution is effective and safe for long-term use in treating eyelash thinning.
37 citations,
January 2010 in “International Journal of Trichology” Bimatoprost helped eyelash growth in nearly half of the patients with a type of eyelash hair loss.
35 citations,
March 2010 in “British journal of dermatology/British journal of dermatology, Supplement” The study showed that mouse eyelashes can be used to study eyelash growth and that bimatoprost makes them longer and more numerous.
34 citations,
October 2015 in “British journal of dermatology/British journal of dermatology, Supplement” Scientists don't fully understand eyelash hair follicle biology, including growth and color, and suggest more research is needed.
30 citations,
August 2009 in “Journal of the American Academy of Dermatology” Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.